[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-337866-105":59,"doc-detail-337866-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","cost-effectiveness-of-talazoparib-for-patients-with-germline-brca12-mutated-her2-negative-advanced-breast-cancer-in-china-and-the-us","Cost-effectiveness of talazoparib for patients with germline BRCA1/2 mutated HER2-negative advanced breast cancer in China and the US","","A cost-effectiveness analysis evaluates talazoparib for advanced breast cancer patients with germline BRCA1/2 mutations and HER2 negativity from health service perspectives in China and the United States. The study uses a Markov model parameterized with survival and clinical transition inputs extracted from the Phase III EMBRACA/EMBRACE trial evidence, with treatment costs sourced from local hospital pricing, references, and expert consultation. Outcomes are measured in QALYs and assessed via deterministic and probabilistic sensitivity analyses. Results indicate talazoparib is cost-effective, extending progression-free survival with improved economic value versus standard therapy.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/cost-effectiveness-of-talazoparib-for-patients-with-germline-brca12-mutated-her2-negative-advanced-breast-cancer-in-china-and-the-us/337866/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/cost-effectiveness-of-talazoparib-for-patients-with-germline-brca12-mutated-her2-negative-advanced-breast-cancer-in-china-and-the-us/337866.png","ImageObject",300,407,{"name":92,"@type":93},"Violet","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-28","2026-09-21",true,{"@type":102,"interactionType":103,"userInteractionCount":39},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What patient population and treatment are evaluated in the study?","Question",{"text":112,"@type":113},"The analysis focuses on advanced breast cancer patients with germline BRCA1/2 mutations and HER2 negativity, comparing talazoparib with standard treatment options.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How does the study estimate costs and health outcomes?",{"text":117,"@type":113},"Costs are based on local hospital pricing, other references, and expert consultation, while health outcomes are expressed as Quality Adjusted Life Years (QALYs).",{"name":119,"@type":110,"acceptedAnswer":120},"What do the results indicate about cost-effectiveness in China and the US?",{"text":121,"@type":113},"From the China perspective, talazoparib incurs an incremental cost of $2484.48 per QALY with an incremental QALY gain of 1.5; in the US perspective, it dominates by saving $10,223.43 and increasing QALYs by 1.5.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},337866,1790179915,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":39,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":41,"preview_page_count":19,"preview_urls":145},4398048950312,"https://ap-avatar.wpscdn.com/avatar/400002538284de19e3c?_k=1778320343897328908","[www. nature.com/scientificreports](www. nature.com/scientificreports)  \nOPEN  \nCost‑effectiveness oftalazoparib for patients with germline BRCA1/2 mutated HER2‑negative advanced breast cancer in China and the US  \nJunjie Pan1,2,3, Ning Ren1, Lanqi Ren1, YiBeiYang1 & Qiaoping Xu2,3*  \nBreast cancer is one of the tumors with the highest prevalence rate among women in the world, and its BRCA1/2 gene is a common mutation site. Talazoparib, as a targeted PARP inhibitor, can effectively control the occurrence and development of breast cancer with BRCA1/2 gene mutation, and play a therapeutic role. Based on the findings from the Phase III EMBRACE trial (NCT01945775 clinical trial), our analysis reveals that the talazoparib group demonstrated a significant extension in progression‑ free survival, along with improved response markers and patient‑reported outcomes when compared to conventional therapies. This study aims to assess the cost‑effectiveness oftalazoparib for treating advanced breast cancer with germline BRCA1/2 mutations and HER2 negativity, considering the perspectives of health services in China and the United States. The results obtained will serve as a valuable reference for promoting rational drug utilization and enhancing medical resource efficiency. To evaluate the cost‑effectiveness ofTalazoparib more scientifically and provide clinicians with chemotherapy options, this paper developed a Markov model based on the EMBRACA clinical trial (clinical Trails.gov No., NCT01945775) to simulate the survival events of breast cancer patients in the Talazoparib group and the standard treatment group. The state transition probability and clinical data of breast cancer patients during treatment were extracted from the phase III EMBRACA clinical trial. The cost data generated during the treatment process comes from local hospital pricing, other references, and expert consultation. This article uses US dollars to calculate the treatment cost and incremental cost‑effectiveness ratio. Health outcomes are expressed in Quality Adjusted Life Years (QALYs). In addition, Outcomes were measured in quality‑adjusted life‑years (QALYs), and incremental cost‑effectiveness ratio, which robustness was evaluated by deterministic and probabilistic sensitivity analyses. This article establishes a Markov model for single‑item sensitivity analysis. The results show that the economic benefits of using Talazoparib as a new treatment strategy in both China and the United States are higher than other drugs, and it is cost‑effective. Compared to the control group, the incremental cost incurred by theTalazoparib treatment group in China was $2484.48/QALY, with an incremental QALY of 1.5. However, Talazoparib in the United States holds a dominant position, saving costs of $10,223.43 and increasing QALYs by 1.5. The clinical treatment effect ofTalazoparib group in BRCA1/2 mutant advanced breast cancer patients is better than that of the standard treatment group, and the progression free survival period is significantly prolonged. From the perspective of medical and health services in China and the United States, theTalazoparib group is more economical than the standard treatment group in treating patients with BRCA1/2 mutant advanced breast cancer.  \nKeywords Talazoparib, Cost-effectiveness, Germline BRCA-mutated, Markov model, Breast cancer  \nBreast cancer is one of the diseases that women often suffer from, and it is also a common cause of cancer death in women1. Breast cancer has become the fifth leading cause of cancer-related deaths. About 25% of female cancer patients worldwide have suffered from breast cancer, and the number of deaths due to breast cancer has reached  \n1Fourth Clinical Medical College of Zhejiang Chinese Medical University, Affiliated Hangzhou First People’s Hospital, Hangzhou 310053, China. 2Department of Clinical Pharmacology, Key Laboratory of Clinical Cancer Pharmacology and Toxicology Research of Zhejiang Province, Cancer Center,","cbCaiduhVnQ91spO","https://ap.wps.com/l/cbCaiduhVnQ91spO","pdf",1651915,12,"English","# Cost-effectiveness objective\n## Model structure and data sources\n## Outcomes and sensitivity analyses\n## Comparative results: China vs. United States","[{\"question\":\"What patient population and treatment are evaluated in the study?\",\"answer\":\"The analysis focuses on advanced breast cancer patients with germline BRCA1/2 mutations and HER2 negativity, comparing talazoparib with standard treatment options.\"},{\"question\":\"How does the study estimate costs and health outcomes?\",\"answer\":\"Costs are based on local hospital pricing, other references, and expert consultation, while health outcomes are expressed as Quality Adjusted Life Years (QALYs).\"},{\"question\":\"What do the results indicate about cost-effectiveness in China and the US?\",\"answer\":\"From the China perspective, talazoparib incurs an incremental cost of $2484.48 per QALY with an incremental QALY gain of 1.5; in the US perspective, it dominates by saving $10,223.43 and increasing QALYs by 1.5.\"}]","Cost-effectiveness of talazoparib for patients with germline BRCA1/2 mutated HER2-negative advanced breast cancer in China and the US | PDF",1790020991,[146,150,154,158],{"page_no":8,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/023abcc9b569224fe62b8e9a805c244d.webp",983,1291,{"page_no":14,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/99b3bdace04a622f56e3635d146d5f81.webp",982,1290,{"page_no":81,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/8b9792e193f350b252aed3215109ab53.webp",981,1289,{"page_no":19,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/659a0549230936bb136e28cb51b0c9e4.webp",980,1287]